Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer.
Elahe A MostaghelBrett T MarckOrpheus KolokythasFelix ChewEvan Y YuMichael T SchweizerHeather H ChengPhillip W KantoffSteven P BalkMary-Ellen TaplinNima SharifiAlvin M MatsumotoPeter S NelsonR Bruce MontgomeryPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Low-circulating adrenal androgen levels are strongly associated with an androgen-poor tumor microenvironment and with poor response to AA. Patients with CRPC with higher serum DHEAS levels may benefit from dual androgen receptor (AR)-pathway inhibition, while those in the lowest quartile may require combinations with non-AR-directed therapy.